SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3.
Hematologic Malignancies
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3.
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
-
O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, United States, 35233
Ochsner Clinic Foundation, New Orleans, Louisiana, United States, 70121
Clinical Research Alliance, Inc., Lake Success, New York, United States, 11042
New York - Presbyterian Hospital, New York, New York, United States, 10032
UNC School of Medicine, Division of Hematology, Chapel Hill, North Carolina, United States, 27599
Bon Secours St. Francis Cancer Center, Greenville, South Carolina, United States, 29607
Baylor Scott & White Health, Dallas, Texas, United States, 75246
MD Anderson, Houston, Texas, United States, 77091
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to
ALL
No
Sellas Life Sciences Group,
Dragan Cicic, MD, STUDY_CHAIR, SELLAS Life Sciences Group, Inc.
2025-12-31